Russia's war economy strains under a widening fuel crisis — rationing across nearly all regions and refinery attrition forcing broader controls — while century-low EU trade cements decoupling; Iran-related fronts stay contained on the US axis even as the regional war simmers, and drone warfare escalation drives defense-tech procurement on both sides.

I merge the two technologist proposals (weight 1.00, Brier 0.24) — the industry-milestone forecast (new pivotal trial, P=0.68) and the regulatory forecast (FDA Breakthrough expansion within 180 days, P=0.62) — because they describe one platform-expansion story, but I anchor the probability on the more robust industry milestone. A validated Phase 3 platform with Moderna shares surging strongly gives the sponsors overwhelming commercial incentive to open new-indication registrational trials; this is a near-standard playbook and thus high-conviction. I moderate to 0.75 rather than higher because the biotech chain's dominant interpretation is 'Political Health Intervention' (vaccine-policy friction, public-trust erosion) — a genuine US regulatory headwind that particularly threatens the faster 180-day FDA-acceleration leg (which I judge closer to a coin-flip and therefore fold into the more durable 12-month trial milestone rather than publish separately). The Skeptic scored these 68-74.